4-氟-2,6-二甲氧基苯甲醛 | 139549-11-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氟-2,6-二甲氧基苯甲醛
• 英文名称: 4-fluoro-2,6-dimethoxybenzaldehyde
• CAS: 139549-11-4
• 化学式: C₉H₉FO₃
• mdl: MFCD12025137
• 分子量: 184.167
• InChiKey: HOGUCRFULNNZBQ-UHFFFAOYSA-N

物化性质

• 熔点：
  79-81 °C
• 沸点：
  268.4±35.0 °C(Predicted)
• 密度：
  1.201±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-氟-2,6-二甲氧基苯甲醛 在 三乙酰氧基硼氢化钠 、 potassium carbonate 、 溶剂黄146 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (1s,3s)-N-(2,6-dimethoxy-4-(3-(phenylamino)phenoxy)benzyl)adamantan-1-amine
  参考文献：
  名称：

  Discovery of 4-(3,5-dimethoxy-4-(((4-methoxyphenethyl)amino)methyl)phenoxy)-N-phenylaniline as a novel c-myc inhibitor against colorectal cancer in vitro and in vivo

  摘要：

  Proto-oncogene c-Myc plays an essential role in the development of colorectal cancer (CRC), since downregulation of c-Myc inhibits intestinal polyposis, which is the most cardinal pathological change in the development of CRC. Herein, a series of novel phenoxy-N-phenylaniline derivatives were designed and synthesized. The cytotoxicity activities of all the derivatives were measured by MTT assay in different colon cancer cells, 4-(3,5-dimethoxy-4-(((4-methoxyphenethyl)amino)methyl)phenoxy)-N-phenylaniline (42) was discovered, the lead compound 42 with excellent cytotoxicity activity of IC50 = 0.32 mu M, IC50 = 0.51 mu M, in HT29 and HCT 15 cells, respectively. Compound 42 had a good inhibitory activity of cMyc/MAX dimerization and DNA binding. Besides, compound 42 could effectively induce apoptosis and induced G2/M arrest in low concentration and G0/G1 arrest in high concentration to prevent the proliferation and differentiation in colon cancer cells. Western blot analysis confirmed the 42 strongly down-regulated expression of c-Myc. Furthermore, during 30 days treatment 42 exhibited excellent efficacy in HT29 tumor xenograft model without causing significant weight loss and toxicity. Consequently, 42 could be a promising drug candidate for CRC therapy. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112336
• 作为产物：
  描述：

  1,3-二甲氧基-5-氟苯 、 N,N-二甲基甲酰胺 在 三氯氧磷 作用下， 反应 4.83h， 以62.3%的产率得到4-氟-2,6-二甲氧基苯甲醛
  参考文献：
  名称：

  苯氧基-N-苯基苯胺衍生物及其应用

  摘要：

  本发明涉及苯氧基‑N‑苯基苯胺衍生物及其应用，属于新型结直肠癌药物技术领域。本发明解决的技术提供一些具有c‑Myc抑制活性的新化合物。该化合物的结构式为式Ⅰ所示。本发明设计合成了一系列新型苯氧基‑N‑苯基苯胺衍生物，该化合物可作为c‑Myc抑制剂使用，对结直肠癌细胞的增殖有较好的抑制作用，为结直肠癌药物提供了新的选择。

  公开号：

  CN111153817B

文献信息

• [EN] IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION<br/>[FR] DÉRIVÉS D'IMIDAZOTHIADIAZOLE ET D'IMIDAZOPYRAZINE UTILISÉS COMME INHIBITEURS DU RÉCEPTEUR 4 ACTIVÉ PAR UNE PROTÉASE (PAR4) POUR LE TRAITEMENT DE L'AGRÉGATION PLAQUETTAIRE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013163279A1

  公开（公告）日：2013-10-31

  The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

  本发明提供了式I的噻唑化合物，其中W、Y、R0、R2、R4、R5、R6、R7、X1、X2、X3和X4如本文所定义，或其立体异构体、互变异构体、药学上可接受的盐、前药酯或溶剂化合物形式，其中所有变量均如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作治疗或预防血栓栓塞性疾病的药物。
• PAR4 AGONIST PEPTIDES
  申请人：Bristol-Myers Squibb Company

  公开号：US20130289238A1

  公开（公告）日：2013-10-31

  The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.

  本发明提供PAR4激动肽。这些肽对于开发强大的PAR4受体测定方法非常有用。
• NOVEL OXAZOLIDINONE DERIVIATIVES
  申请人：Aissaoui Hamed

  公开号：US20120101111A1

  公开（公告）日：2012-04-26

  The present invention relates to oxazolidinone derivatives of formula (I) wherein Y, R 3 and R 4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式(I)的噁唑烷酮衍生物，其中Y、R3和R4如描述中所述，以及它们的制备方法，它们的药用盐，以及它们作为药物的用途，包括含有一个或多个式(I)化合物的药物组合物，特别是它们作为促进睡眠的药物受体拮抗剂的用途。
• [EN] 2,4-DIHYDROXY-NICOTINAMIDES AS APJ AGONISTS<br/>[FR] 2,4-DIHYDROXY-NICOTINAMIDES UTILISÉS EN TANT QU'AGONISTES D'APJ
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017066402A1

  公开（公告）日：2017-04-20

  The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

  本发明提供了式（I）的化合物：其中所有变量如规范中所定义，并包括任何此类新化合物的组合物。这些化合物是APJ激动剂，可用作药物。
• PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS
  申请人：SIRIGIREDDY REDDY

  公开号：US20100152491A1

  公开（公告）日：2010-06-17

  Processes for preparing (E)-2,4,6-(Trimethoxystyryl)-3-O-Phosphate Disodium-4-Methoxybenzyl Sulfones and uses thereof as antiproliferative agents, including, for example, anticancer agents, and as radioprotective and chemoprotective agents.

  制备(E)-2,4,6-(三甲氧基苯乙烯基)-3-O-磷酸二钠-4-甲氧基苯甲基磺酮的方法及其作为抗增殖剂的用途，包括作为抗癌剂，以及作为放射保护和化学保护剂的用途。